Loading…
Corvus Pharmaceuticals, Inc. is projected to rise to $22.01 by 2027, a +40% move from its current price of $15.67. CRVS is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $15.25 | $15.68 | $16.13 | +0.08% |
| Jul 13 | $15.08 | $15.70 | $16.33 | +0.17% |
| Jul 14 | $14.96 | $15.71 | $16.49 | +0.25% |
| Jul 15 | $14.86 | $15.72 | $16.63 | +0.34% |
| Jul 16 | $14.78 | $15.74 | $16.76 | +0.42% |
| Jul 17 | $14.70 | $15.75 | $16.87 | +0.51% |
| Jul 18 | $14.63 | $15.76 | $16.98 | +0.60% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $14.63 | $15.76 | $16.98 | +0.60% |
| Week 2 | $14.27 | $15.86 | $17.62 | +1.19% |
| Week 3 | $14.02 | $15.95 | $18.15 | +1.80% |
| Week 4 | $13.83 | $16.05 | $18.62 | +2.40% |
| Week 5 | $13.67 | $16.14 | $19.06 | +3.01% |
| Week 6 | $13.53 | $16.24 | $19.48 | +3.63% |
| Week 7 | $13.42 | $16.33 | $19.89 | +4.24% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Corvus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company that develops product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States.
The company is incorporated in 2014 and is based in South San Francisco, California, in the Healthcare sector.
Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, atopic dermatitis, hidradenitis suppurativa, autoimmune lymphoproliferative syndrome, and solid tumors monotherapy, and asthma. It also develops ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of first line renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1 clinical trial for the treatment of non-small cell lung cancer. It has a license agreement with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as license agreement with Scripps for the development and commercialization of mupadolimab.
Corvus Pharmaceuticals, Inc. (CRVS) is in the Healthcare sector, with a current price of $15.63 and a market capitalization of $1.31B. It is ranked 2366.
The near-term technical backdrop shows bullish momentum with RSI(14) at 70, and both the 50-day and 200-day simple moving averages trading above $12.29 and $13.47 respectively thresholds are implied by the listed figures; the SMA50 is $13.47 and the SMA200 is $12.29. Near-term support sits at $11.12 and resistance at $15.63. The 30-day price range runs from $12.89 to $18.96, indicating recent volatility within that window.
Longer-term, the forecast portrays a rising trajectory with substantial upside through 2050, including a multi-year path where the average price climbs from $15.63 in 2026 to $30.06 in 2030 and to $185.07 by 2050, with corresponding ROI growth to 1084.1%. The volatility backdrop is noted at 60% annualized. Overall, the outlook is bullish across the extended horizon, though these are estimates and carry inherent uncertainty.
A major floor 41.0% below — a decisive break under it would weaken the trend.
The nearest floor, 29.0% below — buyers have tended to step in here.
The nearest ceiling, 3.4% above — a clean break opens room to run.
A major ceiling 23.9% above — clearing it would confirm fresh momentum.
Key CRVS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CRVS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $15.75 | Sell | $15.67 | Buy |
| MA 10 | $15.16 | Buy | $15.09 | Buy |
| MA 20 | $13.70 | Buy | $14.26 | Buy |
| MA 50 | $13.48 | Buy | $13.86 | Buy |
| MA 100 | $14.64 | Buy | $13.73 | Buy |
| MA 200 | $12.44 | Buy | $12.32 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 68.12 | Neutral |
| Stoch RSI (14) | 67.75 | Neutral |
| CCI (20) | 88.35 | Neutral |
| Williams %R (14) | -14.56 | Info |
| MACD (12,26,9) | 0.33 | Buy |
| ROC (12) | 24.07 | Buy |
| Bollinger %B (20,2) | 0.81 | Neutral |
| Stochastic %K (14) | 85.44 | Sell |
| TRIX (15) | 0.58 | Buy |
| Awesome (5,34) | 2.75 | Buy |
| Ultimate (7,14,28) | 72.16 | Sell |
| Momentum (10) | 2.62 | Buy |
| Aroon Osc (25) | 88.00 | Buy |
| Hull MA (9) | 16.26 | Sell |
| ADX (14) | 29.76 | Buy |
| ATR (14) | 0.36 | Info |
The near-term technical picture is bullish, with RSI(14) at 70 indicating sustained momentum. The price is trading above the key moving averages, with the 50-day SMA at $13.47 and the 200-day SMA at $12.29, suggesting supportive trend dynamics.
Immediate levels to watch are a base near $11.12 and a ceiling near $15.63, which align with the stated resistance and support levels. The 30-day range shows activity between $12.89 and $18.96, highlighting current volatility within a relatively tight band.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $6.50 | $15.67 | $22.32 | 0% | Neutral | |
| $17.47 | $22.01 | $29.36 | +40% | Bullish | |
| $19.96 | $25.87 | $35.85 | +65% | Bullish | |
| $21.89 | $29.07 | $41.49 | +86% | Bullish | |
| $22.44 | $30.43 | $44.52 | +94% | Bullish | |
| $24.85 | $34.35 | $51.37 | +119% | Bullish | |
| $28.54 | $40.17 | $61.24 | +156% | Bullish | |
| $35.04 | $50.16 | $77.85 | +220% | Bullish | |
| $40.54 | $58.97 | $93.00 | +276% | Bullish | |
| $40.26 | $59.47 | $95.21 | +279% | Bullish | |
| $66.08 | $104.65 | $178.45 | +568% | Bullish | |
| $107.09 | $191.28 | $357.48 | +11.2x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $6.50 | $15.67 | $19.30 | +0.00% |
| August 2026 | $13.87 | $16.38 | $19.89 | +4.54% |
| September 2026 | $14.23 | $16.93 | $20.79 | +3.35% |
| October 2026 | $14.88 | $17.82 | $22.09 | +5.27% |
| November 2026 | $14.91 | $17.94 | $22.42 | +0.66% |
| December 2026 | $14.66 | $17.73 | $22.32 | -1.17% |
Click any year to see its month-by-month CRVS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The CRVS price prediction for 2026 points to an average of $15.67 (low $6.50, high $22.32) — a potential gain of 0% on today's $15.67. A consolidation phase looks the most probable path here.
In 2027, CRVS is projected to trade between $17.47 and $29.36, averaging $22.01 — a potential gain of +40% from today's $15.67. That is up +40% on the projected 2026 average. Momentum favours further upside here.
Corvus Pharmaceuticals, Inc.'s 2028 outlook centres on $25.87, within a $19.96 to $35.85 range. That is up +18% on the projected 2027 average. That marks a +65% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, CRVS could reach as high as $41.49, with a base case around $29.07 and support toward $21.89 — roughly +86% from $15.67. Momentum favours further upside here.
Expect CRVS to range from $22.44 to $44.52 through 2030. The $30.43 average target implies a +94% move from current prices. That is up +5% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The CRVS price prediction for 2031 points to an average of $34.35 (low $24.85, high $51.37) — a potential gain of +119% on today's $15.67. Momentum favours further upside here.
In 2032, CRVS is projected to trade between $28.54 and $61.24, averaging $40.17 — a potential gain of +156% from today's $15.67. That is up +17% on the projected 2031 average. Buyers look set to stay in control over this stretch.
Corvus Pharmaceuticals, Inc.'s 2033 outlook centres on $50.16, within a $35.04 to $77.85 range. That is up +25% on the projected 2032 average. That marks a +220% change versus current levels. Momentum favours further upside here.
By 2034, CRVS could reach as high as $93.00, with a base case around $58.97 and support toward $40.54 — roughly +276% from $15.67. Buyers look set to stay in control over this stretch.
Expect CRVS to range from $40.26 to $95.21 through 2035. The $59.47 average target implies a +279% move from current prices. That is up +1% on the projected 2034 average. Momentum favours further upside here.
The CRVS price prediction for 2040 points to an average of $104.65 (low $66.08, high $178.45) — a potential gain of +568% on today's $15.67. Buyers look set to stay in control over this stretch.
In 2050, CRVS is projected to trade between $107.09 and $357.48, averaging $191.28 — a potential gain of +11.2x from today's $15.67. That is up +83% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in CRVS today (≈ 63.816209 CRVS) could be worth
$12,206.57
+$11,206.57 (+1121%) by 2050 · US Dollar
Based on the average projected CRVS price of $191.28 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CRVSwould be worth at today's price.
$1,000 invested in CRVS on Jul 10, 2025 (≈ 235.294118 CRVS) would be worth
$3,687.06
+$2,687.06 (+268.7%) today · 3.69× · US Dollar
Based on a CRVS entry price of $4.25 vs. today's $15.67.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $15.23 | $1,028.89 | +2.9% |
| 1 month ago | $11.16 | $1,404.12 | +40.4% |
| 3 months ago | $15.1 | $1,037.75 | +3.8% |
| 6 months ago | $6.75 | $2,321.48 | +132.1% |
| 1 year ago | $4.25 | $3,687.06 | +268.7% |
| All time (5.0y) ago | $2.49 | $6,293.17 | +529.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CRVS forecast.
Our base-case forecast reaches $31.00 around 2031.
Implied market cap at $31.00: $2.61B
The multi-year forecast paints a strong uptrend through 2050, with the average price advancing from $15.63 in 2026 to $30.06 in 2030 and then to $185.07 by 2050. The corresponding ROI figures rise from 0% in 2026 to 92.3% in 2030, 273.3% by 2035, and an estimated 1084.1% by 2050, signaling substantial long-run upside under the projected path. The optimistic sentiment persists across most years, culminating in a bullish stance for 2040 (avg $102.23, max $176.61) and 2050 (avg $185.07, max $351.27).
Investors should consider the high volatility (annualized 60%) and the inherent uncertainty in long-horizon projections.
Tap a question to reveal the answer.
The forecast for 2030 shows an average price of $30.06 with a min of $22.00 and a max of $44.36, and an estimated ROI of 92.3%; sentiment is bullish.
The forecast exhibits a bullish trajectory after 2026, with year-by-year averages rising (e.g., 2027 avg $22.06, ROI 41.2%; 2035 avg $58.35, ROI 273.3%), and a long-horizon ROI reaching 1084.1% by 2050.
Yes. The 2040 forecast shows an average of $102.23 and a max of $176.61, indicating potential above-$100 levels by 2040.
Current price is $15.63 and market cap is $1.31B.
The 30-day range is $12.89 to $18.96, and annualized volatility is 60%.
Corvus Pharmaceuticals, Inc. Community Discussion
0Share your Corvus Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.